Loading stock data…
$3.94-0.05 (-1.25%)
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States.
SCYNEXIS, Inc. in the Healthcare sector is trading at $3.94 with a market capitalization of $40M. Wall Street consensus targets $36.33 (3 analysts), implying a +822.2% move over the next 12 months. The stock is currently near its 52-week low of $3.53, remaining 29.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $235,000 | $0↓ | $18.65M↑ | $334,000↓ | $1.36M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.78M↑ | -$16.94M↓ | $10.52M↑ | -$8.40M↑ | -$9.56M |
| Net Income | $7.40M↑ | -$21.30M↓ | $12.26M↑ | -$8.59M↓ | -$6.88M |
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vu...